Viewing Study NCT05155566


Ignite Creation Date: 2025-12-24 @ 4:40 PM
Ignite Modification Date: 2026-06-02 @ 12:39 AM
Study NCT ID: NCT05155566
Status: COMPLETED
Last Update Posted: 2024-01-26
First Post: 2021-12-09
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.
Sponsor: Pfizer
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer Metastatic View
Keywords:

Keywords

Keyword Brief Keyword Text View
None human epidermal growth factor receptor 2 negative (HER2-) View
None hormone receptor positive (HR+) View
None advanced breast cancer (ABC) View
None metastatic breast cancer (MBC) View